NOVARTIS
PHARMACEUTICALS

Scapho®
secukinumab

Normal skin. Extraordinary experience.

NOW IN INDIA.

The 1st and only IL^-17A inhibitor targeted for psoriasis[1-7]

- **Achieving PASI# 90 - PASI# 100 is now possible[8]**
- **Normal skin in 16 weeks*[9]**

Basic Succinct Statement Scapho®
Presentation: Secukinumab. Powder for solution for subcutaneous injection.**Indications:Plaque psoriasis** Scapho® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. **Dosage and administration: Plaque psoriasis:**The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg.**Contraindications:**Scapho® is contraindicated in patients who have/had severe hypersensitivity reactions reaction to the active substance or to any of the excipients. **Warnings and precautions: Infections:** Caution in patients with chronic or history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Scapho® should not be administered until the infection resolves. Anti-tuberculosis therapy should be considered prior to initiation of Scapho® in patients with latent tuberculosis. Scapho® should not be given to patients with active tuberculosis. **Crohn's disease:** Patients with active Crohn's disease treated with Scapho® should be followed closely. **Hypersensitivity reactions:** Administration of Scapho® should be discontinued immediately and appropriate therapy initiated if an anaphylactic or other serious allergic reaction occurs.**Vaccinations:** Scapho® should not be given concurrently with live vaccines. **Pregnancy:** Scapho® should be used during pregnancy only if the benefits clearly outweigh the potential risks.**Breast-feeding:** Caution should be exercised when Scapho® is administered to a woman who is breast-feeding.**Adverse drug reactions:Very common (≥10%):** Upper respiratory tract infections (nasopharyngitis, upper respiratory tract infection, rhinitis, pharyngitis, sinusitis, tonsillitis).**Common (1 to 10%):** Oral herpes, diarrhea, urticaria, rhinorrhea. **Uncommon (0.1 to 1%):** Oral candidiasis, neutropenia, tinea pedis, conjunctivitis.**Interactions:**Live vaccines should not be given concurrently with Scapho®. **Packs:** Scapho® 150 mg Powder for Solution for Injection: 1 vial per pack. Before prescribing, please consult full prescribing information available from Novartis Healthcare Private Limited, Sandoz House, Dr. Annie Besant Road, Worli, Mumbai- 400 018, Tel: 022 2495 8888
For the use of only registered medical practitioners or a hospital or a laboratory.
India BSS dtd 22 July 15 based on international BSS dtd 22 Oct 13 effective from 23 July 15.

Journal Ad/Scapho/Derma/522335/02/16

1. Full prescribing information of Scapho India pack insert dated 22nd July 2015 based on IPL dated 22nd October 2013; 2. Johansen C, et al. Brit J Dermatol. 2009; 160:319-24;
3. Arican O, et al. Mediators Inflamm. 2005; Oct 24;2005(5):273-9; 4. Kopf M, et al. Nat Rev Drug Discov. 2010; 9(9):703-18; 5. Chiricozzi A, et al. J Invest Dermatol. 2011;131:677-687;
6. Martin DA, et al. J Invest Dermatol. 2013 Jan;133(1):17-26; 7. Nestle FO, et al. N Engl J Med 2009; 361(5):496-509. 8.Langley RG et al. N Engl J Med 2014; 371(4): 326-38.
9. Thaci D, et al. J Am Acad Dermatol. 2015 Sep;73(3):400-9.
*44% of patients achieve PASI 100 by week 16.
#Psoriasis Area Severity Index
^Interleukin